Ionis Pharmaceuticals Inc’s recently made public that its Officer Schneider Eugene acquired Company’s shares for reported $0.41 million on Aug 04 ’25. In the deal valued at $42.88 per share,9,549 shares were bought.
Then, Monia Brett P sold 2,432 shares, generating $109,440 in total proceeds. Upon selling the shares at $45.00, the Chief Executive Officer now owns 179,820 shares.
Before that, Monia Brett P bought 2,432 shares. Ionis Pharmaceuticals Inc shares valued at $109,440 were divested by the Officer at a price of $45.00 per share.
Morgan Stanley upgraded its Ionis Pharmaceuticals Inc [IONS] rating to an Overweight from a an Equal-weight in a research note published recently. A number of analysts have revised their coverage, including Barclays’s analysts, who increased its forecast for the stock in early July from “an Equal weight” to “an Overweight”. H.C. Wainwright began covering IONS with “Buy” recommendation on April 07, 2025. Redburn Atlantic started covering the stock on March 31, 2025. It rated IONS as “a Neutral”.
Price Performance Review of IONS
On Monday, Ionis Pharmaceuticals Inc [NASDAQ:IONS] saw its stock jump 0.98% to $43.45. Over the last five days, the stock has gained 5.54%. Ionis Pharmaceuticals Inc shares have fallen nearly -12.15% since the year began. Nevertheless, the stocks have risen 24.28% over the past one year.
How much short interest is there in Ionis Pharmaceuticals Inc?
A steep rise in short interest was recorded in Ionis Pharmaceuticals Inc stocks on 2025-07-15, dropping by -1.34 million shares to a total of 12.89 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 14.23 million shares. There was a decline of -10.37%, which implies that there is a negative sentiment for the stock.
